natgillin/translations-raw huggingface dataset:
Conversely, it is anticipated that prokinetic substances such as cisapride may decrease the bioavailability of thiazide- type diuretics.
Nasuprot tome, predviđa se da prokinetički lijekovi kao što je cisaprid mogu smanjiti bioraspoloživost tiazidnih diuretika.
Conversely, other drugs that induce CYP3A4 may also reduce saquinavir plasma concentrations. .
Nasuprot tome, drugi lijekovi koji induciraju CYP3A4 mogu sniziti koncentracije sakvinavira u plazmi.
Conversely, patients > 75 years (n=12) experienced more frequent serious adverse reactions, dose delay, dose reduction and discontinuation compared to patients ≤ 75 years (n=105) when treated with ONIVYDE+5-FU/LV in the pancreatic adenocarcinoma study.
S druge strane, bolesnici >75 godina (n=12) imali su učestalije ozbiljne nuspojave, odgađanje doze, smanjivanje doze i prekid liječenja u usporedbi s bolesnicima ≤ 75 godina (n=105) kad su primali ONIVYDE+5-FU/LV u ispitivanju adenokarcinoma gušterače.
Conversion between Modigraf and Prograf tacrolimus formulations
Prelazak između Modigrafa i Prografa kao formulacija takrolimusa
Conversion from required dose to injection volume and vial strength
Pretvorba potrebne doze u volumen injekcije i jačinu bočice
Conversion of atrial fibrillation to sinus rhythm occurred rapidly (in responders the median time to conversion was 10 minutes from start of first infusion) and sinus rhythm was maintained through 24 hours (97%).
Konverzija fibrilacije atrija u sinusni ritam nastupila je vrlo brzo (u bolesnika koji su odgovorili na liječenje medijan vremena do konverzije iznosio je 10 minuta od početka prve infuzije), a sinusni se ritam održao tijekom 24 sata (97%).
Conversion of Prograf- or Advagraf-treated patients to Envarsus - allograft transplant patients Allograft transplant patients maintained on twice daily Prograf (immediate-release) or Advagraf (once daily) dosing requiring conversion to once daily Envarsus should be converted on a 1:0.7 (mg:mg) total daily dose basis and the Envarsus maintenance dose should, therefore, be 30% less than the Prograf or Advagraf dose.
Prelazak bolesnika koji su primali Prograf ili Advagraf na Envarsus – bolesnici s alogenim presatkom U bolesnika s alogenim presatkom koji uzimaju Prograf (s trenutnim oslobađanjem) dva puta na dan ili Advagraf (jedanput na dan), a moraju prijeći na Envarsus koji se uzima jedanput na dan, prelazak treba biti u omjeru ukupne dnevne doze 1: 0,7 (mg:mg), stoga doza održavanja Envarsusa treba biti 30% manja od doze Prografa ili Advagrafa.
Conversion of Prograf-treated patients to Advagraf
Prelazak s liječenja Prografom na liječenje Advagrafom
Conversion rates at week 120 were highest (73.1%; 68/93) in patients with MDRH&R-TB, 70.5% (31/44) in pre-XDR-TB patients and lowest (62.2%; 23/37) in XDR-TB patients.
Stope konverzije u tjednu 120 bile su najviše (73,1%; 68/93) u bolesnika s MDRH&R-TB, 70,5% (31/44) u bolesnika s pre-XDR-TB i najniže (62,2%; 23/37) u XDR-TB bolesnika.
Conversion rates at week 24 were highest (87.1%; 81/93) in patients with MDRH&R-TB, 77.3% (34/44) in pre-XDR-TB patients and lowest (54.1%; 20/37) in XDR-TB patients.
Stope konverzije u tjednu 24 bile su najveće (87,1%; 81/93) u bolesnika s MDRH&R-TB,, 77,3% (34/44) u bolesnika s pre-XDR-TB i najmanje (54,1%; 20/37) u bolesnika s XDR-TB.
Conversion to or from oral and intravenous administration can be done directly without titration.
Konverzija na ili s peroralne i intravenske primjene može se napraviti direktno bez titracije.
Converting from parenteral anticoagulants to Xarelto
Prelazak bolesnika s parenteralnih antikoagulansa na Xarelto
Converting from Vitamin K Antagonists (VKA) to Xarelto
Prelazak bolesnika s antagonista vitamina K (VKA) na Xarelto
Converting from Xarelto to parenteral anticoagulants
Prelazak bolesnika s lijeka Xarelto na parenteralne antikoagulanse
Converting from Xarelto to Vitamin K antagonists (VKA)
Prelazak bolesnika s lijeka Xarelto na antagoniste vitamina K (VKA)
Converting patients from other levodopa/ dopa-decarboxylase (DDC) inhibitor (carbidopa or benserazide) immediate release medicinal products to Numient
Prelazak bolesnika s drugih lijekova s trenutnim oslobađanjem koji sadrže levodopu/ inhibitor dopa- dekarboksilaze (DDC) (karbidopa ili benzerazid) na Numient
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.
Prebacivanje bolesnika s antagonista vitamina K varfarina (INR 2,0 do 3,0) na rivaroksaban (20 mg) ili s rivaroksabana (20 mg) na varfarin (INR 2,0 do 3,0) produljilo je protrombinsko vrijeme/INR (Neoplastin) više nego aditivno (mogu se uočiti pojedinačne vrijednosti INR do 12), dok su učinci na APTV inhibiciju aktivnosti faktora Xa i potencijal endogenog trombina bili aditivni.
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.
Prelazak bolesnika s antagonista vitamina K, varfarina (INR 2,0 do 3,0) na rivaroksaban (20 mg) ili s rivaroksabana (20 mg) na varfarin (INR 2,0 do 3,0) produljio je protrombinsko vrijeme/INR (Neoplastin) više nego aditivno ( mogu se uočiti pojedinačne vrijednosti INR do 12), dok su učinci na APTV, inhibiciju aktivnosti faktora Xa i endogeni trombinski potencijal bili dodatni.
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.
Prelazak bolesnika s antagonista vitamina K, varfarina (INR 2,0 do 3,0) na rivaroksaban (20 mg) ili s rivaroksabana (20 mg) na varfarin (INR 2,0 do 3,0) produljio je protrombinsko vrijeme/INR (Neoplastin) više nego aditivno (mogu se uočiti pojedinačne vrijednosti INR do 12), dok su učinci na APTV, inhibiciju aktivnosti faktora Xa i endogeni trombinski potencijal bili aditivni.
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.
Prelazak bolesnika s antagonista vitamina K, varfarina (INR 2,0 do 3,0) na rivaroksaban (20 mg) ili s rivaroksabana (20 mg) na varfarin (INR 2,0 do 3,0) produljio je protrombinsko vrijeme/INR (Neoplastin) više nego aditivno (mogu se uočiti pojedinačne vrijednosti INR do 12), dok su učinci na APTV, inhibiciju aktivnosti faktora Xa i endogeni trombinski potencijal bili dodatni.
Convulsion
konvulzija
convulsion
napadaji
convulsion (0.5% vs 0.7%), syncope (0.3% vs 0.3%),
konvulzije (0,5% prema 0,7%), sinkopa (0,3% prema
convulsion (fits)
konvulzije (napadaji)
convulsion (fits), fainting, a restless urge to move parts of your body, dizziness upon standing, disturbance in attention, problems with speech, loss or abnormal sense of taste, reduced sensation of skin to pain and touch, a sensation of tingling, pricking, or numbness of skin
konvulzije (napadaji), kratkotrajna nesvjestica, nestrpljiva potreba za pokretanjem dijelova tijela, omaglica nakon ustajanja, poremećaj pažnje, problem s govorom, gubitak ili nenormalan osjet okusa, smanjen osjećaj kože na bol i dodir, osjećaj peckanja, bockanja ili obamrlosti kože
convulsion (fits), fainting, a restless urge to move parts of your body, dizziness upon standing, disturbance in attention, problems with speech, loss or abnormal sense of taste, reduced sensation of skin to pain and touch, a sensation of tingling, pricking, or numbness of skin
konvulzije (napadaji), nesvjestica, nestrpljiva potreba za pokretanjem dijelova tijela, omaglica nakon ustajanja, poremećaj pažnje, problemi s govorom, gubitak ili nenormalan osjet okusa, smanjen osjećaj kože na bol i dodir, osjećaj trnaca, bockanja ili obamrlosti kože
Convulsion (seizure)
konvulzije (napadaji)
convulsion (“fit”), blood or clots in stool (or black, tarry stool),
konvulzije ("napadaji"), krv ili krvni ugrušci u stolici (ili crna, katranasta stolica).
convulsion a specific liver enzyme (gamma GT) which is produced by your liver, may rise (this will show up in blood tests)
konvulzije može doći do porasta specifičnog jetrenog enzima (gama glutamiltransferaza) kojeg proizvodi Vaša jetra (to se utvrđuje krvnim pretragama)
Convulsion Dizziness
konvulzije omaglica
Convulsion Headache
konvulzija glavobolja
Convulsion#
konvulzije#
Convulsion****
konvulzije
Convulsion*.
Konvulzije
convulsion, a specific liver enzyme (gamma GT) which is produced by your liver, may rise (this will show up in blood tests),
konvulzije, specifičan jetreni enzim (gama glutamiltransferaza) kojeg stvara Vaša jetra, mogao bi porasti (to će se vidjeti na krvnim pretragama),
convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling)
konvulzije, poremećaj ravnoteže, omaglica (osjećaj nestabilnosti), letargija (nedostatak energije i elana), tremor (nevoljno drhtanje)
convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
konvulzije, poremećaj ravnoteže, omaglica (osjećaj nestabilnosti), bezvoljnost (gubitak energije i entuzijazma), tremor (nevoljno drhtanje);
convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
konvulzije, poremećaj ravnoteže, omaglica (osjećaj nestabilnosti), bezvoljnost (nedostatak energije i volje), tremor (nevoljno drhtanje);
convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
konvulzije, poremećaj ravnoteže, omaglica (osjećaj nestabilnosti), letargija (nedostatak energije i elana), tremor (nevoljno drhtanje);
convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
konvulzije, poremećaj ravnoteže, omaglica (osjećaj nestabilnosti), letargija (nedostatak energije i entuzijazma), tremor (nevoljno drhtanje);
convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness),lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
konvulzije, poremećaj ravnoteže, omaglica (osjećaj nestabilnosti), letargija (nedostatak energije i elana), tremor (nevoljno drhtanje);
convulsion, balance disorder (equilibrium disorder),dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
konvulzije, poremećaj ravnoteže, omaglica (osjećaj nestabilnosti), bezvoljnost (nedostatak energije i volje), tremor (nevoljno drhtanje);
Convulsion, clonus, brain oedema
konvulzije, klonus, edem mozga
Convulsion, febrile convulsion.
Konvulzija, febrilna konvulzija.
Convulsion, hypertonia, tremor, somnolence, headache, paraesthesia
konvulzije, hipertonija, tremor, somnolencija, glavobolja, parestezija
Convulsion, hypertonia, tremor, somnolence, myasthenic syndrome, dizziness, headache, paraesthesia, dysgeusia
konvulzije, hipertonija, tremor, somnolencija, mijastenični sindrom, omaglica, glavobolja, parestezija, disgeuzija
Convulsion, Paraesthesia
konvulzije, parestezija
convulsion, syncope, tremor, hypertonia3, paraesthesia, somnolence, dizziness
konvulzije, sinkopa, tremor, hipertonija3, parestezija, somnolencija, omaglica
convulsion, syncope, tremor, hypertonia3, paraesthesia, somnolence, dizziness
konvulzije, sinkopa, tremor, hipertonija3, parestezija, somnolencija, vrtoglavica
Convulsion, Tremor, Somnolence, Burning sensation
konvulzije, tremor, somnolencija, osjećaj pečenja
Convulsion, vertigo
konvulzija, vrtoglavica
Convulsion: narrow SMQ “Convulsions”
Konvulzije: suženi SMQ “Konvulzije”
Convulsion: narrow SMQ “Convulsions”
Konvulzije: uski SMQ “Konvulzije”
Convulsion^; Syncope; Dizziness ; Paraesthesia^;
konvulzije^; sinkopa; omaglica; parestezije^;
convulsiond,
parestezija
convulsione
konvulzijae
convulsions
konvulzije
convulsions (fits or seizures);
konvulzija (napadaji),
Convulsions (fits)
konvulzije (napadaji grčenja)
Convulsions (fits) linked to hypoglycaemia (abnormally low blood sugar levels),
Konvulzije (napadaji) povezane s hipoglikemijom (neuobičajeno niska razina šećera u krvi),
Convulsions (may affect up to 1 in 100 people) – convulsions (fits) are when a person's body shakes rapidly and uncontrollably.
Konvulzije (mogu se javiti u do 1 na 100 osoba) – konvulzije (napadaji) su kada se tijelo osobe brzo i nekontrolirano trese.
Convulsions (with or without fever)
konvulzije (praćene vrućicom ili bez nje)
Convulsions and delirium, including altered level of consciousness
konvulzije i delirij, uključujući promjenu razine svijesti
Convulsions disorders
Konvulzije
Convulsions have been observed in patients receiving efavirenz, generally in the presence of a known medical history of seizures.
U pacijenata koji primaju efavirenz uočene su konvulzije, obično uz pozitivnu anamnezu napadaja.
Convulsions have been reported in patients treated concomitantly with orlistat and antiepileptic medicinal products e.g. valproate, lamotrigine, for which a causal relationship to an interaction cannot be excluded.
Prijavljene su konvulzije u bolesnika koji su istodobno primali orlistat i antiepileptike, npr. valproat, ili lamotrigin, pri čemu se ne može isključiti mogućnost da je to posljedica interakcije.
Convulsions or pronounced excitation: treat with benzodiazepines
konvulzije ili izraziti nemir: liječiti benzodiazepinima
Convulsions with or without fever*
Konvulzije sa ili bez vrućice
Convulsions with or without fever, occurring within 3 days of vaccination.
Konvulzije, s vrućicom ili bez nje, koje se javljaju unutar 3 dana nakon cijepljenja.
Convulsions with or without fever, occurring within 3 days of vaccination.
Konvulzije, sa ili bez vrućice, unutar 3 dana od cijepljenja.
Convulsions, consciousness decreased, somnolence, aphasia, balance impaired, dizziness, confusion, memory impairment, concentration impaired,
konvulzije, smanjena razina svijesti, somnolencija, afazija, poremećaj ravnoteže, omaglica, konfuzija, narušeno pamćenje, narušena koncentracija, neuropatija, parestezije, poremećaj govora, tremor
Convulsions, consciousness decreased, somnolence, aphasia, balance impaired, dizziness, confusion, memory impairment, concentration impaired, neuropathy, paraesthesia, speech disorder, tremor
konvulzije, smanjena razina svijesti, somnolencija, afazija, poremećaj ravnoteže, omaglica, konfuzija, narušeno pamćenje, narušena koncentracija, neuropatija, parestezije, poremećaj govora, tremor
Convulsions, consciousness decreased, somnolence, aphasia, balance impaired, dizziness, confusion, memory impairment, concentration impaired, neuropathy, paresthesia, speech disorder, tremor
konvulzije, smanjena razina svijesti, somnolencija, afazija, poremećaj ravnoteže, omaglica, konfuzija, narušeno pamćenje, narušena koncentracija, neuropatija, parestezija, poremećaj govora, tremor
Convulsions, consciousness decreased, somnolence, aphasia, balance impaired, dizziness, confusion, memory impairment, concentration impaired, neuropathy, paresthesia, speech disorder, tremor
konvulzije, smanjena razina svijesti, somnolencija, afazija, poremećaj ravnoteže, omaglica, konfuzija, narušeno pamćenje, narušena koncentracija, neuropatija, parestezije, poremećaj govora, tremor
Convulsions, eye swelling and anaphylaxis.
Konvulzije, oticanje oka i anafilaksija.
convulsions, fits or seizures fainting
konvulzije, napadaji nesvjestica
Convulsions, including status epilepticus and grand mal convulsions, may occur during pregabalin use or shortly after discontinuing pregabalin.
Tijekom ili nedugo nakon prekida primjene pregabalina mogu se javiti konvulzije, uključujući status epilepticus i grand mal napadaje.
Convulsions, increased tension in the muscles, shaking and muscle weakness, joint pain
grčevi, povećana mišićna napetost, drhtanje i slabost mišića, bol u zglobovima
Convulsions, nerve problems
konvulzije (epileptički napadaji), tegobe sa živcima
convulsions, neuropathy, hypoaesthesia, tremor, aphasia,
konvulzije, neuropatija, hipoestezija, tremor, afazija,
Convulsions, parosmia, hypokinesia, dysgraphia
konvulzije, parosmija, hipokinezija, disgrafija
Convulsions, sudden onset of sleep (see section 4.4), trismus, restless legs syndrome
konvulzije, napadaj iznenadnog nastupa sna (vidjeti dio 4.4), trizmus, sindrom nemirnih nogu
Convulsions, syncope, transient ischaemic attack, unresponsiveness to stimuli, depressed level of consciousness, tremor, somnolence
konvulzije, sinkopa, tranzitorna ishemijska ataka, odsustvo reakcije na podražaje, smanjena razina svijesti, tremor, somnolencija
Convulsions.
konvulzije
convulsions3, amnesia3, thinking abnormal3, ataxia3, coordination abnormal3, agitation3, tremor
konvulzije3, amnezija3, abnormalno razmišljanje3, ataksija3, abnormalna koordinacija3, agitacija3, tremor
Cooling of the injection site, warming the injection liquid, use of cold packs (before and after the injection), and use of topical corticosteroids and antihistamines after the injection can alleviate the signs and symptoms of injection site reactions.
Hlađenje mjesta primjene, ugrijavanje injekcijske tekućine, uporaba hladnih obloga (prije i nakon primjene) i topikalna primjena kortikosteroida i antihistaminika nakon primjene mogu ublažiti znakove i simptome reakcija na mjestu primjene.
Cooling procedures such as ice packs should have been removed from the area at least 15 min before the Savene administration in order to allow sufficient blood flow.
Postupci hlađenja, kao što su ledeni oblozi, moraju biti uklonjeni s tog područja barem 15 minuta prije primjene lijeka Savene kako biste omogućili dostatan protok krvi.
Coolock Dublin 17 Ireland
Coolock Dublin 17 Irska
Coombs direct test positive, oxygen saturation decreased
pozitivan direktni Coombsov test, smanjeno zasićenje kisikom
Coombs test positive, blood pressure systolic decreased, blood pressure systolic increased, body temperature increased
Pozitivan Coombsov test, snižen sistolički krvni tlak, povišen sistolički krvni tlak, povišena tjelesna temperatura
Coombs test positive, increased serum gamma-glutamyl transpeptidase (GGT), increased serum alkaline phosphatase
pozitivan rezultat Coombsovog testa, povišene vrijednosti gama-glutamil transpeptidaze (GGT) u serumu, povišene vrijednosti alkalne fosfataze u serumu
Coombs` direct test positive (Coombs` test positive), decreased haemoglobin (including decreased haematocrit, decreased haptoglobin), increased alanine aminotransferase, increased blood lactate dehydrogenase, increased aspartate aminotransferase
Pozitivni Coombsov direktni test,( pozitivni Coombsov test), sniženi hemoglobin (uključujući sniženi hematokrit, sniženi haptoglobin), povišena alanin aminotransferaza, povišena razina laktat dehidrogenaze u krvi, povišena aspartat aminotransferaza
Coombs’ test positive, decreased haemoglobin (including decreased haematocrit, decreased haptoglobin), increased alanine aminotransferase, increased blood lactate dehydrogenase, increased aspartate aminotransferase).
Pozitivni Coombs-ov test), sniženi hemoglobin (uključujući sniženi hematokrit, sniženi haptoglobin) , povišenu alanin aminotransferazu, povišenu laktat dehidrogenazu u krvi, povišenu aspartat aminotransferazu).
Cooppallaan 9, B-9230 Wetteren, Belgium
Cooppallaan 9, B-9230 Wetteren, Belgija
Coordination abnormal
Poremećaj koordiancije
Coordination abnormal Vertigo
aoteškoće s koordinacijom vrtoglavica
Coordination abnormal Vertigo
poteškoće s koordinacijom vrtoglavica
Coordination abnormal, memory impairment, amnesia, hypersomnia, sedation, aphasia, dysaesthesia, dystonia, lethargy, parosmia, cerebellar syndrome, convulsion, peripheral neuropathy, nystagmus, speech disorder, dysarthria, burning sensation, paresthesia, migraine
Abnormalna koordinacija, oštećenje pamćenja, amnezija, hipersomnija, sedacija, afazija, disestezija, distonija, letargija, parosmija, cerebelarni sindrom, konvulzije, periferna neuropatija, nistagmus, poremećaji govora, dizartrija, osjećaj žarenja, parestezija, migrena
Copalia 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Copalia 5 mg/160 mg.
Copalia 10 mg/160 mg se može primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 10 mg ili valsartanom 160 mg ili s Copaliom 5 mg/160 mg.
Copalia 5 mg/80 mg tablets are round and dark yellow with “NVR” on one side and “NV” on the other side.
Copalia 5 mg/80 mg tablete su okrugle, tamnožute tablete, s oznakom „NVR“ na jednoj strani i „NV“ na drugoj strani.
Copalia and older people (age 65 years or over)
Copalia i starije osobe (starosti od 65 ili više godina)
Copalia has not been studied in any patient population other than hypertension.
Copalia nije ispitivana ni u jednoj drugoj populaciji bolesnika, osim u bolesnika s hipertenzijom.
Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Copalia HCT 10 mg/160 mg/12,5 mg filmom obložene tablete amlodipin/valsartan/hidroklorotiazid
Copalia HCT 10 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Copalia HCT 10 mg/160 mg/25 mg filmom obložene tablete amlodipin/valsartan/hidroklorotiazid
Copalia HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Copalia HCT 10 mg/320 mg/25 mg filmom obložene tablete amlodipin/valsartan/hidroklorotiazid
Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Copalia HCT 5 mg/160 mg/12,5 mg filmom obložene tablete amlodipin/valsartan/hidroklorotiazid
Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets are white, oval tablets with “NVR” on one side and “VCL” on the other side.
Copalia HCT 5 mg/160 mg/12,5 mg filmom obložene tablete su bijele, ovalne tablete s oznakom „NVR“ na jednoj strani i „VCL“ na drugoj strani.
Copalia HCT 5 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Copalia HCT 5 mg/160 mg/25 mg filmom obložene tablete amlodipin/valsartan/hidroklorotiazid
Copalia is available in packs containing 7, 14, 28, 30, 56, 90, 98 or 280 tablets and in multipacks comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets.
Copalia je dostupan u pakovanjima koja sadrže 7, 14, 28, 30, 56, 90, 98 ili 280 tableta i u višestrukim pakovanjima koji sadrže 4 kutije, od kojih svaka sadrži 70 tableta, ili 20 kutija, od kojih svaka sadrži 14 tableta.
Copalia is available in packs containing 7, 14, 28, 30, 56, 90, 98 or 280 tablets and in multipacks comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets.
Copalia je dostupna u pakovanjima koja sadrže 7, 14, 28, 30, 56, 90, 98 ili 280 tableta i u višestrukim pakovanjima koji sadrže 4 kutije, od kojih svaka sadrži 70 tableta, ili 20 kutija, od kojih svaka sadrži 14 tableta.
Copalia is contraindicated in patients with severe hepatic impairment (see section 4.3).
Copalia je kontraindiciran u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
Copalia is contraindicated in patients with severe hepatic impairment (see section 4.3).
Copalia je kontraindicirana u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).